pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
Nektar Therapeutics UK clinical programs — 57 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
Nektar Therapeutics UK projects
57 ClinicalTrials.gov programs sponsored by Nektar Therapeutics UK.
Nektar Therapeutics UK has 57 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
LY3471851
Nektar Therapeutics UK Limited
Dermatitis, Atopic
1 trial -
LY3471851
Nektar Therapeutics UK Limited
Healthy
4 trials -
NKTR-102
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-181
Nektar Therapeutics UK Limited
Moderate to Severe Chronic Pain
1 trial -
NKTR-214
Nektar Therapeutics UK Limited
Advanced Cancer
1 trial -
NKTR-255
Nektar Therapeutics UK Limited
Multiple Myeloma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Renal Cell Carcinoma
1 trial -
Placebo
Nektar Therapeutics UK Limited
Psoriasis
1 trial -
TAK-659
Nektar Therapeutics UK Limited
Lymphoma, Non-Hodgkin
1 trial
Frequently asked questions
How many clinical projects does Nektar Therapeutics UK have?
57 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.